• 1
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 11821186.
  • 2
    Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004; 255: 538561.
  • 3
    McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003; 361: 1959.425
  • 4
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 23352342.
  • 5
    Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 2004; 9 Suppl 1: 1926.
  • 6
    Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390: 335336.
  • 7
    Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20: 7986.
  • 8
    Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 2004; 58: 914926.
  • 9
    Kimura H, Nakajima T, Kagawa K, Deguchi T, Kakusui M, Katagishi T, et al. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver 1998; 18: 1419.
  • 10
    Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001; 116: 838845.
  • 11
    Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 2004; 130: 307319.
  • 12
    Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99: 1139311398.
  • 13
    Kong HL, Hecht D, Song W, Kovesdi I, Hackett NR, Yayon A, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998; 9: 823833.
  • 14
    Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001; 7: 20572066.
  • 15
    Schuppan D, Cramer T, Bauer M, Strefeld T, Hahn EG, Herbst H. Hepatocytes as a source of collagen type XVIII endostatin. Lancet 1998; 352: 879880.
  • 16
    Musso O, Theret N, Heljasvaara R, Rehn M, Turlin B, Campion JP, et al. Tumor hepatocytes and basement membrane-producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. HEPATOLOGY 2001; 33: 868876.
  • 17
    Musso O, Rehn M, Theret N, Turlin B, Bioulac-Sage P, Lotrian D, et al. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res 2001; 61: 4549.
  • 18
    Morris H, Wagner B, Ray F, Sewart H, Snell K. Carcinogenesis effects of N,N′-465 2,7-fluorenylenebis-2,2,2-trifluoroacetamide (2,7-FAA-F6) administered orally to Buffalo strain rats. J Nat Cancer Inst 1963; 30: 143161.
  • 19
    Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 1998; 143: 13411352.
  • 20
    De Valck V, Geerts A, Schellinck P, Wisse E. Localization of four phosphatases 470 in rat liver sinusoidal cells: an enzyme cytochemical study. Histochemistry 1988; 89: 357363.
  • 21
    Nikol S, Armeanu S, Engelmann MG, Pelisek J, Fuchs A, Zahringer C, et al. Evaluation of endovascular techniques for creating a porcine femoral artery occlusion model. J Endovasc Ther 2001; 8: 401407.
  • 22
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 19071917.
  • 23
    Schwartz JD, Schwartz M, Goldman J, Lehrer D, Coll D, Kinkabwala M, et al. Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. In: ASCO Annual Meeting, Abstr. 4088; 2004.
  • 24
    Li P, Yuan M, Xia H. Experimental study of the therapeutic effects of an antiendothelial cell monoclonal antibody BVE-1 for solid tumor xenograft in nude mice. Zhonghua Zhong Liu Za Zhi 1998; 20: 280283.
  • 25
    Ruiz J, Mazzolini G, Sangro B, Qian C, Prieto J. Gene therapy of hepatocellular carcinoma. Dig Dis 2001; 19: 324332.
  • 26
    Trübenbach J, Graepler F, Pereira PL, Ruck P, Lauer U, Gregor M, et al. Growth characteristics and imaging properties of the Morris Hepatoma 3924A in ACI rats: a suitable model for transarterial chemoembolization. Cardiovasc Intervent Radiol 2000; 23: 211217.
  • 27
    Lang I, Pabst MA, Hiden U, Blaschitz A, Dohr G, Hahn T, et al. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur J Cell Biol 2003; 82: 163173.
  • 28
    Aird WC. Endothelial cell heterogeneity. Crit Care Med 2003; 31: S221230.
  • 29
    Gouysse G, Frachon S, Hervieu V, Fiorentino M, d'Errico A, Dumortier J, et al. Endothelial cell differentiation in hepatocellular adenomas: implications for histopathological diagnosis. J Hepatol 2004; 41: 259266.
  • 30
    Mahasreshti PJ, Kataram M, Wang MH, Stockard CR, Grizzle WE, Carey D, Siegal GP, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003; 9: 27012710.
  • 31
    Ishikawa H, Nakao K, Matsumoto K, Ichikawa T, Hamasaki K, Nakata K, et al. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. HEPATOLOGY 2003; 37: 696704.
  • 32
    Dhar DK, Ono T, Yamanoi A, Soda Y, Yamaguchi E, Rahman MA, et al. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 2002; 95: 21882195.
  • 33
    Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649663.
  • 34
    Benezra R, Rafii S. Endostatin's endpoints: deciphering the endostatin antiangiogenic pathway. Cancer Cell 2004; 5: 205206.
  • 35
    O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277285.
  • 36
    Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000; 60: 15031506.
  • 37
    Rowe PM. What is all the hullabaloo about endostatin? Lancet 1999; 353: 732.
  • 38
    Sun H, Zhang M, Tang Z, Li X, Wang L, Gao D, Xue Q, et al. Endostatin inhibited the growth of human HCC subcutaneously implanted in nude mice. Chin J Exp Surg 1999; 16: 491492.
  • 39
    Sun H, Zhang M, Tang Z, Wang L, Li X, Gao D, et al. Endostatin inhibited growth and metastasis of human HCC transplanted in nude mice after resection. Chin J Oncol 2000; 22: 469470.
  • 40
    Schmitz V, Wang L, Barajas M, Gomar C, Prieto J, Qian C. Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 2004; 53: 561567.
  • 41
    Li L, Wu PH, Huang JL, Liu RY, Zeng YX, Huang WL. Inhibitive effects of recombinant adenovirus-mediated human endostatin on the growth of human hepatocellular carcinoma xenograft in nude mice. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 542545.
  • 42
    Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261276.
  • 43
    Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004; 11: 10771084.